| 0.68 0.03 (4.62%) | 11-11 09:40 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.82 | 1-year : | 0.87 |
| Resists | First : | 0.7 | Second : | 0.75 |
| Pivot price | 0.67 |
|||
| Supports | First : | 0.62 | Second : | 0.52 |
| MAs | MA(5) : | 0.66 |
MA(20) : | 0.67  |
| MA(100) : | 0.77 |
MA(250) : | 1.21 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 27.7 |
D(3) : | 26.8 |
| RSI | RSI(14): 50.3 |
|||
| 52-week | High : | 2.5 | Low : | 0.51 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BCLI ] has closed below upper band by 43.8%. Bollinger Bands are 68% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 67 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.67 - 0.67 | 0.67 - 0.68 |
| Low: | 0.63 - 0.64 | 0.64 - 0.64 |
| Close: | 0.63 - 0.64 | 0.64 - 0.65 |
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Thu, 06 Nov 2025
Brainstorm Cell Therapeutics Secures New Financing Agreement - TipRanks
Wed, 29 Oct 2025
Brainstorm Cell Therapeutics (BCLI) Price Target Decreased by 13.95% to 17.34 - Nasdaq
Mon, 27 Oct 2025
Halper Sadeh LLC Encourages Brainstorm Cell Therapeutics Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
Thu, 14 Aug 2025
BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
Fri, 08 Aug 2025
BrainStorm Cell Therapeutics Sets Key Q2 Earnings Call: Stem Cell Pipeline and Financial Updates Coming - Stock Titan
Fri, 08 Aug 2025
BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 10 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 11.9 (%) |
| Held by Institutions | 3.4 (%) |
| Shares Short | 604 (K) |
| Shares Short P.Month | 537 (K) |
| EPS | -1.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.61 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -180.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.4 |
| PEG Ratio | 0 |
| Price to Book value | -1.14 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|